Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10736559 | 0.96 | MAPT (0.60) | MAPTKMT2ACYP2C9CYP2D6CYP2C19 | |
| SCHEMBL7546685 | 0.94 | MAPT (0.59) | MAPTKMT2ACYP2C9CYP2D6CYP2C19 | |
| SCHEMBL18256805 | 0.94 | MAPT (0.59) | MAPTKMT2ACYP2C9CYP2D6CYP2C19 | |
| SCHEMBL7536680 | 0.94 | MAPT (0.59) | MAPTKMT2ACYP2C9CYP2D6CYP2C19 | |
| SCHEMBL7544659 | 0.94 | MAPT (0.59) | MAPTKMT2ACYP2C9CYP2D6CYP2C19 | |
| SCHEMBL7544666 | 0.94 | MAPT (0.59) | MAPTKMT2ACYP2C9CYP2D6CYP2C19 | |
| SCHEMBL7536641 | 0.94 | MAPT (0.59) | MAPTKMT2ACYP2C9CYP2D6CYP2C19 | |
| SCHEMBL7941127 | 0.92 | MAPT (0.55) | MAPTKMT2ACYP2C9CYP2D6CYP2C19 | |
| SCHEMBL7238826 | 0.86 | MAPT (0.50) | MAPTKMT2AKDM4EHSD17B10HPGD | |
| SCHEMBL16479572 | 0.85 | CYP2D6 (0.66) | MAPTKMT2ACYP2C9CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4580405-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | Oerth Bio LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024050016-A9 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2024050016-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | OERTH BIO LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-2925762-B1 | TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SUNOVION PHARMACEUTICALS INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-9670230-B2 | Heteroaryl compounds and methods of use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9567355-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-12-08 | — | — | US | disclosed |
| US-9453007-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| CN-101679261-A | Piperazine and piperidine mglur5 potentiators | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| WO-2010011964-A2 | IMAGING AGENTS USEFUL FOR IDENTIFYING AD PATHOLOGY | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| EP-2134687-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | AstraZeneca AB (SE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
| EP-0433457-B1 | ANTIPRURITIC COMPOSITION | SHISEIDO CO LTD (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5219847-A | Antipruritic composition | SHISEIDO COMPANY, LTD. (JP) | 1993-06-15 | — | — | US | disclosed |
| EP-0433457-A1 | ANTIPRURITIC COMPOSITION | SHISEIDO COMPANY LIMITED (JP) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | APP, APBA1, PYGB | MAPT 9/4885KMT2A 3496/4885CYP2C9 4579/4885 |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | MAPT 2485/4885KMT2A 1931/4885CYP2C9 3001/4885 |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | MAPT 4059/4885KMT2A 4446/4885CYP2C9 796/4885 |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | MAPT 4059/4885KMT2A 4446/4885CYP2C9 796/4885 |
| US-20260068886-A1 | COMPOSITIONS AND METHODS FOR TARGETED INHIBITION AND DEGRADATION OF PROTEINS IN AN INSECT CELL | CRBN, STUB1, CUL1 | MAPT 3939/4885KMT2A 1480/4885CYP2C9 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.